Description
This study reveals extensive tauopathy in a 7-year-old brain with ADNP mutation, contradicting the established view that tauopathy primarily occurs in aging brains. The developmental versus degenerative mechanisms underlying early-onset tauopathy remain unexplained and could fundamentally alter our understanding of tau pathology.
Gap type: contradiction Source paper: Tauopathy in the young autistic brain: novel biomarker and therapeutic target. (None, None, PMID:32661233)
Resolution criteria
Resolution requires: (1) Comparative transcriptomics or proteomics of brains from ADNP mutation carriers (n>=3, age <=40) vs late-onset AD cases (n>=3, age >=70) vs controls, identifying >=5 genes or pathways uniquely dysregulated in ADNP-related tauopathy; (2) Cellular models (iPSC neurons from ADNP mutation carriers) demonstrating that restored ADNP function (gene therapy or small molecule activation) reduces tau phosphorylation and aggregation by >=50%; (3) Mechanistic link: ADNP-regulated genes involved in microtubule dynamics or protein phosphatases directly cause tau pathology when disrupted. Genotype-phenotype correlation without mechanistic pathway dissection is insufficient.